The following links are to sites we find valuable
- 1. SNM 2012 Image of the Year: Bi-213-DOTATOC for a New Treatment for GEP-NET Tumors Resistant to Standard Therapies:
- (In the News)
- Miami Beach, Fla. – The Society of Nuclear Medicine's (SNM) 2012 Image of the Year illustrates the effectiveness of Bi-213-DOTATOC for the peptide receptor alpha-therapy of gastroenteropancreatic neuroendocrine ...
- Created on 20 June 2012
- 2. Updates from the Ga68 Working Group
- (News)
- ... trials. In October 2013, the Society of Nuclear Medicine and Molecular Imaging (SNMMI) received orphan drug designation for Ga-68 DOTATOC. Click hereto see the slides from the Gallium Information Session ...
- Created on 18 August 2014
- 3. Ga68 - Orphan Drug Announcement
- (In the News)
- BREAKING NEWS – the radiopharmaceutical Gallium-68 (DOTA0-hel-Tyr3) octreotide (Ga-68 DOTATOC) has been designated as an orphan drug by the US Food and Drug Administration (FDA) for the management of neuroendocrine ...
- Created on 20 November 2013
- 4. Susan's Stor
- (Bad Berka)
- ... more in one week about my carcinoid than we had in the previous 10 years. This was mostly due to the Gallium-68 DOTATOC PET/CT Scan and Dr. Baum's experience in treating over 1,000 patients. The scan ...
- Created on 28 January 2012
- 5. Road to Basel - Terry Y.
- (Basel)
- ... days stay PRRT injection cost: 6000 CHF (Y90 DOTATOC) Total: 9240 CHF (CHF – Canton Helvetica Franc -- is the notation for Swiss currency. Switzerland is not a European Union country. Therefore, ...
- Created on 12 June 2011
- 6. 1st World Congress on Ga-68 and Peptide Receptor Radionuclide Therapy
- (In the News)
- 1st World Congress on Ga-68 and Peptide Receptor Radionuclide Therapy THERANOSTICS – on the Way to Personalized Medicine Since 1997, when he first used the radiolabeled peptide Y-90 DOTATOC (a somatostatin ...
- Created on 07 April 2011
- 7. Information for Referring Physicians
- (General MD)
- ... by OctreoScan or (preferable) by Ga-68 DOTATOC PET/CT. * Renal function and blood counts should be in the normal range. * Small bowel tumors (midgut), progressive under octreotide (Sandostatin, Somatuline) ...
- Created on 19 July 2010